Aclaris Therapeutics, Inc. ACRS
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Aclaris Therapeutics, Inc. (ACRS) is a healthcare company listed in the US with a market value of about $622M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$80M, a net margin of -1244.1%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -52%.
About Aclaris Therapeutics
Aclaris Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $2M in 2017 to $8M in 2025, growth of about 21.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 673% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $8M | $19M | $31M | $30M | $7M | $6M | $4M | $6M | $2M | — |
| Net income | -$80M | -$65M | -$132M | -$88M | -$87M | -$91M | -$51M | -$161M | -$133M | -$69M | -$48M |
| Free cash flow | -$75M | -$47M | -$20M | -$80M | -$68M | -$52M | -$39M | -$98M | -$102M | -$56M | -$35M |
| EPS (diluted) | $-0.58 | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 | $-3.90 | $-4.03 | $-2.44 | $-2.25 |
| Net margin | -1244.1% | -829.6% | -705.5% | -283.2% | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% | — |
| ROIC | — | -57.4% | -70.9% | -60.3% | -35.5% | -35.4% | -97.9% | -118.6% | -27.3% | -23.5% | -22.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $10.36, 164% above the current price; targets range from $4.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.60 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Aclaris Therapeutics pay a dividend?
Not currently.
Is Aclaris Therapeutics a good stock to buy?
We do not give buy or sell advice. Aclaris Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.